
Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target
Vanda Pharmaceuticals (VNDA) Analyst Ratings
Bulls say
Vanda Pharmaceuticals is witnessing strong growth in its product portfolio, particularly with Ponvory experiencing record new patient prescriptions following its launch, indicating robust underlying demand that is expected to translate into significant gross sales of $172.8 million by 2034. Fanapt also showed impressive performance, with revenue growth of 27% in 2Q25 and 31% in 3Q25, suggesting an annualized run-rate nearing $120 million, alongside a marked increase in new prescriptions. The ongoing investments in prescriber awareness and the anticipated impact of bipolar approval on Fanapt's sales momentum reinforce a positive outlook for the company's commercial strategy and revenue potential.
Bears say
Vanda Pharmaceuticals Inc. reported net product sales of $7.1 million in 2Q25, which marked an 18% year-over-year decline, and faced significant disruption from recent changes in distribution and pricing structures following its December 2024 acquisition. The company anticipates a rapid erosion of exclusivity by the end of 2027 for key products like Fanapt, exacerbated by competition from generics and transitioning patient preferences towards alternatives with better reimbursement terms. Additionally, Vanda's commercial traction is hindered by challenges in the flare segment and risks related to regulatory setbacks and potential dilution from future acquisitions, all contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Vanda Pharmaceuticals (VNDA) Analyst Forecast & Price Prediction
Start investing in Vanda Pharmaceuticals (VNDA)
Order type
Buy in
Order amount
Est. shares
0 shares